Navigation Links
Researchers identify potential biomarker for AD
Date:7/28/2014

(Boston)-- Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. These findings appear in the Annals of Neurology.

AD is the most frequent age-related dementia affecting 5.4 million Americans including 13 percent of people age 65 and older, and more than 40 percent of people age 85 and older. Genetic factors account for much of the risk for developing AD with heritability estimates between 60 percent and 80 percent. However much of the genetic basis for the disease is unexplained. Less than 50 percent of the genetic contribution to AD is supported by known common genetic variations.

Using data from the Framingham Heart Study, the researchers obtained strong evidence of an association with several single nucleotide polymorphism in PLXNA4, a gene which had not been previously linked to AD. They then confirmed this finding in a larger dataset from the Alzheimer's Disease Genetics Consortium and other datasets. Next, they performed a series of experiments in models that pinpointed the mechanism by which this gene affects AD risk. "Importantly, this is one of few single studies which go from gene finding to mechanism," explained corresponding author Lindsay Farrer, PhD, Chief of Biomedical Genetics and professor of medicine, neurology, ophthalmology, epidemiology and biostatistics at BUSM.

According to the researchers a form of the protein encoded by this gene promotes formation of neurofibrillary tangles consisting of decomposed tau protein, one of the two pathological hallmarks of the disease. "We showed that PLXNA4 affects the processing of tau as it relates to neurofibrillary tangles, the primary marker of AD. Most drugs that have been developed or that are in development for treating AD are intended to reduce the toxic form of beta-amyloid, a sticky substance that accumulates in the brain of persons with AD, and none have been very effective. Only a few drugs have targeted the tau pathway," added Farrer.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. BU researchers discover that Klotho is neuroprotective against Alzheimers disease
2. Researchers discover new way to determine cancer risk of chemicals
3. A world first: Researchers identify a treatment that prevents tumor metastasis
4. Researchers unlock the protein puzzle
5. Communication about female condom vital to young adults, UT Arlington researchers say
6. Feinstein Institute researchers identify brain network
7. CNIO researchers discover a gene that links stem cells, ageing and cancer
8. University of Houston researchers create new method to draw molecules from live cells
9. Researchers Spot Potential New Culprit Behind Alzheimers
10. Researchers demonstrate health risks posed by third hand tobacco smoke
11. Chinese researchers describe impaired self-face recognition in those with major depressive disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
(Date:4/24/2017)... ... 2017 , ... As part of the nationwide Days of Remembrance effort led ... Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced ... trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip ...
(Date:4/24/2017)... ... 2017 , ... Sean Fay is the undisputed king of the infomercial. With ... the George Foreman Grill (which sold more than 100 million units worldwide), he has ... , Now, due to changes in the broadcast media landscape, the once ever-present infomercial ...
(Date:4/24/2017)... ... , ... My T Chai, a South African company that creates a number ... RevNutrition.com, a popular website specializing in sales of nutritional products. , Chai tea ... Siam. It spread across Asia and Africa quickly, and today recipes vary from region ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: